Cancer Genetics, Inc. Merger (Tables)
|9 Months Ended|
Sep. 30, 2021
|Business Combination and Asset Acquisition [Abstract]|
|Schedule of Preliminary Allocation of the Purchase Price Consideration||
The following details the preliminary allocation of the purchase price consideration recorded on March 31, 2021, with adjustments recorded in the second and third quarters of 2021, and balances as of September 30, 2021.
Schedule of Preliminary Allocation of the Purchase Price Consideration
|Schedule of Proforma Financial Information||
The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020:
Schedule of Proforma Financial Information
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef